The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index; none of the 76 sources its claims cite is checked for support yet.
ALARM NMR for HTS Triage and Chemical Probe Validation
Open accessAbstract
Nonspecific target engagement by test compounds and purported chemical probes is a significant source of assay interference and promiscuous bioactivity in high‐throughput screening (HTS) and chemical biology. Most counter‐screens for thiol‐reactive compounds utilize mass spectrometry or fluorescence detection, as well as nonproteinaceous reporters like glutathione that may not always approximate the reactivity of protein side chains. By contrast, a L a a ssay to detect r eactive m olecules by n uclear m agnetic r esonance (ALARM NMR) is an industry‐developed protein‐based [1 H‐13 C]‐heteronuclear multiple quantum coherence NMR counter‐screen to identify nonspecific protein interactions by test compounds by reporting their tendencies to modulate the human La antigen conformation. This article is a user's guide to the production of the 13 C‐labeled La antigen reporter protein and reaction of test compounds with this reporter protein, as well as the collection and analysis of characteristic NMR spectra. Combined with other assay interference counter‐screens, this assay will enhance chemical biology by helping researchers better prioritize chemical matter, which will increase the number of tractable HTS screening actives and aid in the development of better chemical probes. © 2018 by John Wiley & Sons, Inc.
Overview
CoChat Summary
TL;DR
ALARM NMR is a protein-based [1H-13C]-HMQC counter-screen using a 13C-methyl-labeled human La antigen reporter to flag thiol-reactive or nonspecific protein-perturbing compounds in HTS triage and chemical probe validation. This Current Protocol provides step-by-step methods for producing the labeled La reporter protein, running the ±DTT assay, and interpreting the resulting NMR spectra.
Key findings
- ALARM NMR detects thiol-reactive compounds through DTT-dependent decreases and/or shifts at 13C-labeled leucine peaks L249, L294, and L296; nonspecific/aggregating compounds perturb the La antigen conformation independent of DTT, while nonreactive compounds such as fluconazole show minimal changes.
- In one drug discovery setting, 10/34 (29%) compounds negative by conventional GSH reactivity screens were flagged as thiol-reactive by ALARM NMR; some HTS campaigns had ALARM NMR-positive hit rates approaching 50%.
- The protocol reports 13C-methyl incorporation can exceed 90%, expected protein yield >20 mg per L bacterial culture, default assay conditions of 50 μM protein and 400 μM test compound (8:1 compound:protein) ±20 mM DTT, and that approximately 50% of total cysteines must be covalently modified to trigger an ALARM NMR-positive readout.
- Chemical probes (+)-JQ1, A395, T-26c, and GSK-6853, as well as targeted covalent modulators ibrutinib and FM-381, are ALARM NMR-negative; ampicillin is negative, while more reactive cephalosporins are ALARM NMR-positive.
Methods
- Basic Protocol 1 expresses human La antigen residues 100–324 with N- and C-terminal 6xHis tags from pET28b+ in Rosetta(DE3)pLysS cells in M9 media; 13C-methyl labels are incorporated using [3-13C]-α-ketobutyrate (200 mg/L) and [3,3-13C]-α-ketoisovalerate (300 mg/L), followed by 1 mM IPTG induction, Ni-NTA purification, dialysis, and storage.
- Basic Protocol 2 reduces the La reporter with 20 mM DTT and dialyzes under N2; reactions contain 50 μM protein, 400 μM test compound, 25 mM sodium phosphate pH 7.0, 10% D2O, with or without 20 mM DTT, incubated at 37 °C for 1 h then room temperature for 16 h before [1H-13C]-HMQC/HSQC acquisition at 310 K.
- Data analysis is qualitative: L249/L294/L296 peak intensities and shifts are compared to DMSO controls; >~30% intensity reduction is scored positive, 10–30% equivocal, and <10% negative; DTT-dependent positives are thiol-reactive, while DTT-independent positives indicate nonspecific perturbation.
Limitations
- Stated in the paper: ALARM NMR requires NMR instrumentation, 13C-labeled amino acid precursors are costly, and high protein/compound concentrations can be problematic for poorly soluble compounds or samples with trace impurities; a negative ALARM NMR result does not conclusively exclude thiol reactivity against other proteins, and the assay does not identify reactivity at lysine residues.
- Stated in the paper: the readout is qualitative, aggregators can perturb the La antigen independent of DTT, and rare redox-active compounds may perturb only in the presence of DTT; ALARM NMR-positive compounds are usually deprioritized, but tractable compounds may still react with the La reporter.
- Evident from the text: this is a methods protocol rather than a primary validation study, and throughput is constrained by protein production (approximately one week) and NMR time (~25 min per sample; ~45 min per compound), although several hundred compounds per week is claimed with appropriate instrumentation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 5 Not valid · 52 Not checked · 47 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These perturbations are significantly attenuated when excess DTT is present in the reaction buffer (Figure 1B).”
§ ALARM NMR for HTS triage and chemical probe validation > Introduction
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This compound shows reproducible DTT-dependent activity versus the La antigen reporter protein (Figure 5) (Dahlin et al., 2015c).”
§ ALARM NMR for HTS triage and chemical probe validation > Commentary > Interpreting the results
What the sources say
- Not matchedcites Dahlin et al., 2015c
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Based on titrations of a prototypical thiol-reactive compound, approximately 50% of the total cysteines in an ALARM NMR solution must be covalently modified to trigger an ALARM NMR-positive readout (JL Dahlin and MA Walters, forthcoming results).”
§ ALARM NMR for HTS triage and chemical probe validation > Commentary > Critical parameters
What the sources say
- Not matchedcites JL Dahlin and MA Walters, forthcoming results
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both compounds grossly perturb the La antigen reporter protein conformation independent of DTT (Figure 5, compare blue and red contours and also peak intensities to DMSO spectra).”
§ ALARM NMR for HTS triage and chemical probe validation > Commentary > Interpreting the results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With particularly reactive compounds such as CPM, the difference between the DTT and DTT-free spectra can be highly pronounced.”
§ ALARM NMR for HTS triage and chemical probe validation > Commentary > Interpreting the results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 104 claims and to verify the 56 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 41
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ ALARM NMR for HTS triage and chemical probe validation > BASIC PROTOCOL 2 - ALARM NMR counter-screen > Incubation of test compounds and ALARM NMR protein
“default final concentrations for ALARM NMR are 50 μM protein in 25 mM sodium phosphate buffer, pH 7.0, 10% D2O, ± 20 mM DTT, and later 400 μM test compound delivered from DMSO stocks). Prepare the DTT reaction solution: To a microcentrifuge tube, add 100 μL D2O, 95 μL 10× ALARM NMR buffer, 735 μL H2O, 50 μL protein stock solution, 20 μL DTT.”
§ ALARM NMR for HTS triage and chemical probe validation > BASIC PROTOCOL 2 - ALARM NMR counter-screen > Incubation of test compounds and ALARM NMR protein
“For this example, assume a 500 μM protein stock solution.”
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Pervushin, K., Riek, R., Wider, G., & Wüthrich, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12366 · Cited by 2,445
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940 · cited 1×
“Some commonly used molecular probes are also thiol-reactive (Baell, 2010; Baell, Ferrins, Falk, & Nikolakopoulos, 2013; Dahlin, Nissink, Strasser, et al., 2015).”
Protein production and purification
Structural Genomics Consortium, Biologiques, A. E. F. D. M., Berkeley Structural Genomics Center, China Structural Genomics Consortium, Integrated Center for Structure and Function Innovation, Israel Structural Proteomics Center, Joint Center for Structural Genomics, Midwest Center for Structural Genomics, New York Structural GenomiX Research Center for Structural Genomics, Northeast Structural Genomics Consortium, et al. (2008) · Nature Methods · doi:10.1038/nmeth.f.202 · Cited by 916
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Self-citationSchanda, P., Kupče, Ē., & Brutscher, B. (2005) · Journal of Biomolecular NMR · doi:10.1007/s10858-005-4425-x · Cited by 709
Bowers, E. M., Yan, G., Mukherjee, C., Orry, A., Wang, L., Holbert, M. A., Crump, N. T., Hazzalin, C. A., Liszczak, G., Yuan, H., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.006 · Cited by 666
Tugarinov, V., Hwang, P. M., Ollerenshaw, J. E., & Kay, L. E. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030153x · Cited by 649
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V., Ravindran, A., Sadhale, P. P., & Kundu, T. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402839200 · Cited by 546
Small Molecule Modulators of Histone Acetyltransferase p300
Balasubramanyam, K., Swaminathan, V., Ranganathan, A., & Kundu, T. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301580200 · Cited by 515
Goto, N. K., Gardner, K. H., Mueller, G. A., Willis, R. C., & Kay, L. E. (1999) · Journal of Biomolecular NMR · doi:10.1023/a:1008393201236 · Cited by 512
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
Dahlin, J. L., Nissink, J. W. M., Strasser, J. M., Francis, S., Higgins, L., Zhou, H., Zhang, Z., & Walters, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5019093 · Cited by 351
Self-citationTugarinov, V., & Kay, L. E. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030345s · Cited by 347
An Isotope Labeling Strategy for Methyl TROSY Spectroscopy
Tugarinov, V., & Kay, L. E. (2004) · Journal of Biomolecular NMR · doi:10.1023/b:jnmr.0000013824.93994.1f · Cited by 253
Gardner, K. H., & Kay, L. E. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9706514 · Cited by 250
Jadhav, A., Ferreira, R. S., Klumpp, C., Mott, B. T., Austin, C. P., Inglese, J., Thomas, C. J., Maloney, D. J., Shoichet, B. K., & Simeonov, A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901070c · Cited by 238
One‐Dimensional SDS Gel Electrophoresis of Proteins
Gallagher, S. R. (2012) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1002as97 · Cited by 234
Huth, J. R., Mendoza, R., Olejniczak, E. T., Johnson, R. W., Cothron, D. A., Liu, Y., Lerner, C. G., Chen, J., & Hajduk, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0455547 · Cited by 228
The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2306 · Cited by 224
NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups
Hajduk, P. J., Augeri, D. J., Mack, J., Mendoza, R., Yang, J., Betz, S. F., & Fesik, S. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja000350l · Cited by 209
Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding
Coan, K. E. D., Maltby, D. A., Burlingame, A. L., & Shoichet, B. K. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801605r · Cited by 204
Giannetti, A. M., Koch, B. D., & Browner, M. F. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700952v · Cited by 189
Observations on Screening-Based Research and Some Concerning Trends in the Literature
Baell, J. B. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.237 · Cited by 179
Site-Specific Reactivity of Nonenzymatic Lysine Acetylation
Baeza, J., Smallegan, M. J., & Denu, J. M. (2015) · ACS Chemical Biology · doi:10.1021/cb500848p · Cited by 169
Jöst, C., Nitsche, C., Scholz, T., Roux, L., & Klein, C. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006918 · Cited by 162
Gardner, K. H., Zhang, X., Gehring, K., & Kay, L. E. (1998) · Journal of the American Chemical Society · doi:10.1021/ja982019w · Cited by 150
Forster, M., Chaikuad, A., Bauer, S. M., Holstein, J., Robers, M. B., Corona, C. R., Gehringer, M., Pfaffenrot, E., Ghoreschi, K., Knapp, S., et al. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.10.008 · Cited by 126
Arif, M., Vedamurthy, B. M., Choudhari, R., Ostwal, Y. B., Mantelingu, K., Kodaganur, G. S., & Kundu, T. K. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.06.014 · Cited by 119
Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Dahlin, J. L., Nelson, K. M., Strasser, J. M., Baršytė-Lovejoy, D., Szewczyk, M. M., Organ, S. L., Cuellar, M. E., Singh, G., Shrimp, J. H., Nguyen, N. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01657-3 · Cited by 113
Self-citationJacks, A. J., Babon, J. J., Kelly, G. P., Manolaridis, I., Cary, P. D., Curry, S., & Conte, M. R. (2003) · Structure · doi:10.1016/s0969-2126(03)00121-7 · Cited by 107
Johnston, P. A., Soares, K. M., Shinde, S. N., Foster, C. A., Shun, T. Y., Takyi, H. K., Wipf, P., & Lazo, J. S. (2008) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2008.151 · Cited by 103
Soares, K. M., Blackmon, N., Shun, T. Y., Shinde, S. N., Takyi, H. K., Wipf, P., Lazo, J. S., & Johnston, P. A. (2010) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2009.0247 · Cited by 93
Wilson, J. M., Wu, D., Motiu-DeGrood, R., & Hupe, D. J. (1980) · Journal of the American Chemical Society · doi:10.1021/ja00521a058 · Cited by 89
PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening
Baell, J. B., Ferrins, L., Falk, H., & Nikolakopoulos, G. (2013) · Australian Journal of Chemistry · doi:10.1071/ch13551 · Cited by 84
Rossi, P., Xia, Y., Khanra, N., Veglia, G., & Kalodimos, C. G. (2016) · Journal of Biomolecular NMR · doi:10.1007/s10858-016-0074-5 · Cited by 72
Self-citationHuth, J. R., Song, D., Mendoza, R. R., Black-Schaefer, C. L., Mack, J. C., Dorwin, S. A., Ladror, U. S., Severin, J. M., Walter, K. A., Bartley, D. M., et al. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700319t · Cited by 71
GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
Bamborough, P., Barnett, H. A., Becher, I., Bird, M. J., Chung, C.-W., Craggs, P. D., Demont, E. H., Diallo, H., Fallon, D. J., Gordon, L. J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00092 · Cited by 67
Metal‐Chelate Affinity Chromatography
Petty, K. J. (1996) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps0904s04 · Cited by 59
Nara, H., Sato, K., Naito, T., Mototani, H., Oki, H., Yamamoto, Y., Kuno, H., Santou, T., Kanzaki, N., Terauchi, J., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.025 · Cited by 57
Metal chelate affinity chromatography
Hubert, P., & Porath, J. O. (1980) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)84764-0 · Cited by 51
Olson, M. E., Li, M., Harris, R. S., & Harki, D. A. (2012) · ChemMedChem · doi:10.1002/cmdc.201200411 · Cited by 42
McCallum, M. M., Nandhikonda, P., Temmer, J. J., Eyermann, C. J., Simeonov, A. M., Jadhav, A., Yasgar, A., Maloney, D. J., & Arnold, A. (. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113476090 · Cited by 34
A Competitive Fluorescence Assay to Measure the Reactivity of Compounds
Epps, D. E. V., & Taylor, B. M. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5173 · Cited by 32
NMR Methods for Identification of False Positives in Biochemical Screens: Miniperspective
Zega, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01520 · Cited by 28
Dahlin, J. L., Nissink, J. W. M., Francis, S., Strasser, J. M., John, K., Zhang, Z., & Walters, M. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.020 · Cited by 19
Self-citationChapter 38 Determination of Protein Purity
Rhodes, D. G., & Laue, T. M. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)63038-x · Cited by 19
Arsovska, E., Trontelj, J., Zidar, N., Tomašič, T., Mašič, L. P., Kikelj, D., Plavec, J., & Zega, A. (2014) · PubMed · Cited by 19
Wei, C., Chupak, L. S., Philip, T., Johnson, B. M., Gentles, R. G., & Drexler, D. M. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113492852 · Cited by 9
Jacks, A., Kelly, G., Curry, S., & Conte, M. R. (2002) · Journal of Biomolecular NMR · doi:10.1023/a:1014928117895 · Cited by 5
Determination of Purity and Yield
Mohan, S. B. (2003) · Humana Press eBooks · doi:10.1385/0-89603-213-2:307 · Cited by 2
Research works printed but not linked: 1
- Dahlin J. L., 2015, Assay guidance manual
Cited by
NMR as a “Gold Standard” Method in Drug Design and Discovery
Emwas, A.-H. M., Szczepski, K., Poulson, B. G., Chandra, K., McKay, R. T., Dhahri, M., Alahmari, F., Jaremko, Ł., Lachowicz, J. I., & Jaremko, M. (2020) · Molecules · doi:10.3390/molecules25204597 · Cited by 155
Ahmad, I. I., Kuznetsov, A. E., Pirzada, A. S., Alsharif, K. F., Daglia, M., & Khan, H. Z. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1145974 · Cited by 124
Ahmad, I. I., Khan, H. Z., & Serdaroğlu, G. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107861 · Cited by 102
Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A
Leaver, D. J., Cleary, B., Nguyen, N. H., Priebbenow, D. L., Lagiakos, H. R., Sanchez, J., Xue, L., Huang, F., Sun, Y., Mujumdar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00665 · Cited by 50
Self-citationReference compounds for characterizing cellular injury in high-content cellular morphology assays
Dahlin, J. L., Hua, B. K., Zucconi, B. E., Nelson, S. D., Singh, S., Carpenter, A. E., Shrimp, J. H., Lima‐Fernandes, E., Wawer, M. J., Chung, L. P. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36829-x · Cited by 49
Self-citation
Metadata
- Authors
- Dahlin, J. L., Cuellar, M., Singh, G., Nelson, K. M., Strasser, J. M., Rappe, T., Xia, Y., Veglia, G., & Walters, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Minnesota (US)
- ORCID
- Venue
- Current Protocols in Chemical Biology
- Publisher
- Wiley
- Published
- 2018-03
- Volume
- 10
- Issue
- 1
- Pages
- 91-117
- ISSN
- 2160-4762 (ISSN-L)
- PMC
- PMC6053072
- OpenAlex
- W2797960269
- Semantic Scholar
- 1a55e599510892350f2d0e86d366699bffeffefb
- Cited by
- 25
- References
- 58
- Citations by year
- 2026: 3 · 2023: 6 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Current Protocols in Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Minnesota Foundation
- National Institutes of Health
- Directorate for Biological Sciences
- National Institute of General Medical Sciences (R01GM100310)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced NMR Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- La antigen, nonspecific protein binding, high-throughput screening, HMQC, assay interference, protein conformation
- MeSH terms
- Humans, Proteins, Reproducibility of Results, Molecular Probes, Leukocyte Common Antigens, Nuclear Magnetic Resonance, Biomolecular, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.